2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1319

Diagnostic Value Of Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis
Abstract Number: 513

Diagnostic Value Of Labial Minor Salivary Gland Biopsy For Primary Sjögren’s Syndrome
Abstract Number: 680

Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma
Abstract Number: 34

Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Abstract Number: 1463

Dietary Impact On Treatment Results Of Methotrexate In Patients With Rheumatoid Arthritis
Abstract Number: 2271

Dietary Sodium Increases The Risk For Rheumatoid Arthritis Among Smokers – Results From a Nested Case-Control Study
Abstract Number: 2248

Difference Between The Two Versions Of Disease Activity Score Based On C-Reactive Protein and Erythrocyte Sedimentation Rate
Abstract Number: 177

Differences and Overlap Of Immunological Pathways Implicated In The Aetiology Of Anti-Citrullinated Peptide Antibody Positive and Negative Rheumatoid Arthritis
Abstract Number: 2450

Differences and Similarities Of Spondyloarthritis Classification Subgroups Defined By The Assessment Of Spondyloarthritis International Society (ASAS)
Abstract Number: 2910

Differences In Abatacept Use In Rheumatoid Arthritis Patients Across Europe: A Pan-European Database Analysis Of Abatacept In European RA Registries
Abstract Number: 2105

Differences In Spinal Mobility Measures In Relation To Disease Duration and Between Subgroups With Axial Spondyloarthritis
Abstract Number: 551

Different Cell Death Programs Contribute To Severity Of Lupus Glomerulonephritis In Males and Females
Abstract Number: 1517

Different Imaging Abnormalities Suggestive Of Spondyloarthritis Are Present In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Abstract Number: 707

Different Location and Extent Of Impaired Perfusion Of The Choroid Plexus In Primary and Secondary Raynaud’s Phenomenon
Abstract Number: 411

Differential Effects of biologics On The Removal Of Amyloid Deposition Between The Kidney and Gastric Tract Of Amyloid A Amyloidosis Patients With Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].